Pharmaceuticals
Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation
* The positive CHMP opinion is based on results from the Phase II PHAROS trial,[1] which demonstrated an objective response rate (ORR) of 75% in treatment-naïve patients and 46% in previously treated patients. The safety profile is consistent with that observed in the approved metastatic melano...
MHX Jakarta 18-21 July 2024 Wrapped Up with Record Turnout, High Leads Generation and Strategic Partnerships
JAKARTA, Indonesia, July 26, 2024 /PRNewswire/ -- Malaysia Healthcare Travel Council (MHTC) achieved impressive results in numerous fronts inJakarta! MHTC is the pioneer in organising healthcare expo inIndonesia and the inaugural event was in Semarang in 2012. MHTC has successfully organised two ...
CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer
* Sugemalimab becomes the world's first anti-PD-L1 monoclonal antibody (mAb) approved inEurope for first-line treatment of both squamous and non-squamous non-small cell lung cancer (NSCLC), also marking the first successful international approval of aChina domestic anti-PD-L1 mAb. * The Europ...
Vantage Markets Reveals "The Future of HealthTech" in the Latest Episode of The Vantage View
PORT VILA, Vanuatu, July 26, 2024 /PRNewswire/ -- Leading multi-asset broker,
Vantage Markets
Vantage Australia Explores HealthTech's Future in the Latest Episode of The Vantage View
SYDNEY, July 26, 2024 /PRNewswire/ -- Leading multi-asset broker, Vantage
Markets
Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development
SAN FRANCISCO and SUZHOU, China, July 26, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...
Australasian College of Pharmacy and MedAdvisor Solutions Launch MedAdvisor software training for the Queensland Community Pharmacy Scope of Practice Pilot
Uplifting pharmacists' role in primary care and positioning pharmacies as essential care destinations in local communities CAMBERWELL, Australia, July 25, 2024 /PRNewswire/ -- MedAdvisor Solutions and the Australasian College of Pharmacy today announced the launch of the MedAdvisor software tra...
Telix Successfully Prices A$650 Million Convertible Bonds
MELBOURNE, Australia, July 24, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) is pleased to announce that it has successfully pricedA$650 million 2.375 per cent convertible notes due 2029. The convertible notes, also referred to as "convertible bond...
Telix Announces A$600 Million Convertible Bonds Offering
MELBOURNE, Australia, July 23, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) today launches an offering ofA$600 million of convertible notes due 2029 (the Offering). The convertible notes, also referred to as "convertible bonds" (Convertible Bonds)...
Linical Named Best Global CRO by Global Health & Pharma Magazine
OSAKA, Japan, July 23, 2024 /PRNewswire/ -- Linical, a global Contract Research Organization (CRO) for full-service drug development, has been awarded the title ofBest Global CRO 2024 by Global Health & Pharma (GHP) Magazine. The award comes as part of the publication's annual Global Excellence A...
QDX Announces Collaboration with Prelude Therapeutics on Novel Oncology Programs
SINGAPORE, July 23, 2024 /PRNewswire/ -- QDX
Valinor Pharma Announces Acquisition by Grünenthal with a Total Deal Value of Approximately $250 Million
* Grünenthal acquires Valinor Pharma in an all-stock deal and becomes the owner of the global rights to Movantik® (naloxegol) * Valinor Pharma had owned Movantik since early 2023 and leveraged Apollo Care's commercial platform to grow Movantik volume in the U.S. while reducing gross-to-net a...
Nature Study Reveals: AI and Molecular Dynamics Designed BGM0504 Exhibits Superior Potency
SHANGHAI, July 22, 2024 /PRNewswire/ -- The molecular design strategy and experimental results of Bright Gene's dual GLP-1/GIP receptor agonist, BGM0504, have been published online in Scientific Reports, a sub-journal of Nature, on July 19, 2024. Bright Gene (Stock Code: 688166.SH) is an innovativ...
Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial
* Obese and overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline of -11.15%, -13.22%, -14.25%, -17.29%, and -17.78%, respectively, with the placebo group at -0...
Everest Medicines Announces First Chinese Patient Dosed in Global Phase 2b PALIZADE Trial of Zetomipzomib in Lupus Nephritis
SHANGHAI, July 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first Chinese patient has be...
Innovent Announces the Second Phase 3 Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
SAN FRANCISCO and SUZHOU, China, July 22, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ...
Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms
* Financing led by LongRiver Investments with participation by new and existing global investment funds * Rona will use proceeds to progress leading metabolic siRNA pipeline programs into global development and expand extra-hepatic delivery platform in CNS and beyond SHANGHAI, July 19, 2024 /...
DX&VX is on Track and Accelerating the Development of Oral Obesity Treatment
* Confirmation of effects compared to global late-stage clinical trials * Accelerating the development of obesity treatment through early licensing out, global joint clinical trials, research funding investment, etc. SEOUL, South Korea, July 18, 2024 /PRNewswire/ -- DX&VX, which is gaining att...
Pfizer's First Dual Indication Vaccine for Respiratory Syncytial Virus (RSV) is Available This Month in Hong Kong
* The first and only bivalent, single-dose vaccine that fights against both RSV A and RSV B has been approved by health authorities inHong Kong and Macau earlier, and is available inHong Kong this month (July 2024) * Helps fight against RSV in older adults aged 60 and above and infants (throu...
Everest Medicines Announces Official Acceptance Granted on NEFECON® Supplementary Application by China National Medical Products Administration
SHANGHAI, July 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced thatChina's National Medical Products ...
Week's Top Stories
Most Reposted
3rd Agri-Food Tech Expo Asia Returns in November 2024 to Champion Innovative, Sustainable and Secure Food Systems
[Picked up by 337 media titles]
2024-07-24 15:30InCorp Global announces Executive Appointments in Singapore and Malaysia respectively
[Picked up by 332 media titles]
2024-07-23 08:00World-famous Greek restaurant estiatorio Milos opens its first Asian location at Marina Bay Sands
[Picked up by 302 media titles]
2024-07-25 10:30ARKANCE Strengthens Support for Autodesk Water Infrastructure Clients Through Partnership with Covey Associates
[Picked up by 300 media titles]
2024-07-24 13:10CYFIRMA Transforms Global Brand Protection with Advanced Cyber and Digital Risk Intelligence through New Partnership with Meltwater
[Picked up by 294 media titles]
2024-07-25 09:00